Evidence map›Paper›PMID 31013269›Full record

ArticlePloS one2019

High content analysis enables high-throughput nematicide discovery screening for measurement of viability and movement behavior in response to natural product samples.

Jennifer M Petitte, Mary H Lewis, Tucker K Witsil, Xiang Huang, John W Rice

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jennifer M PetitteNovozymes North America, Incorporated, Durham, NC, United States of America.
Mary H LewisNovozymes North America, Incorporated, Durham, NC, United States of America.
Tucker K WitsilNovozymes North America, Incorporated, Durham, NC, United States of America.
Xiang HuangNovozymes North America, Incorporated, Durham, NC, United States of America.
John W RiceNovozymes North America, Incorporated, Durham, NC, United States of America.ORCID 0000-0001-5713-5430
Novozymes (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Historically, monitoring nematode movement and mortality in response to various potential nematicide treatments usually involved tedious manual microscopic analysis. High-content analysis instrumentation enables rapid and high-throughput collection of experimental data points on large numbers of individual worms simultaneously. The high-throughput platform outlined here should accelerate discovery of unique classes and types of promising lead molecules and sample types to control these plant pests. Also, the ability to automate the data analysis pipeline rather than relying on manual scoring reduces a potential source of data variance. Here we describe a high-throughput process based on high-content imaging. We demonstrate the use of time-lapse image acquisition to measure movement, and viability staining to confirm nematode mortality (versus paralysis) in targeted plant-pathogenic nematodes. We present screening results from a microbial-exudate library generated from approximately 2,300 microbial fermentations that demonstrate the robustness of this high-throughput process. The described methods should be applicable to other relevant nematode parasites with human, crop, or animal hosts.

Indexed as

Antinematodal AgentsBiological ProductsPest Control, BiologicalAnimalsHumansNematodaPlantsAntinematodal AgentsBiological Products

Identifiers

PMID31013269
PMCPMC6478374
OpenAlexW2941120124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.